Q-omics provides the consensus-scored RPL31P17 profile across patient tissues and cancer cell-line models. RPL31P17 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPL31P17 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, RPL31P17 RNA expression shows 10,434 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where RPL31P17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL31P17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL31P17 survival associations across molecular data types. RPL31P17 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL31P17 RNA expression–survival associations across cancer types. High RPL31P17 expression shows unfavorable associations in ACC, KIRP and SARC, but favorable associations in BLCA, THCA and MESO. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPL31P17 RNA expression.
This table summarizes RPL31P17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL31P17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL31P17 shows lower tumor expression in BRCA and UCEC and higher tumor expression in KIRC, COAD, LIHC and KIRP. The KIRC box plot shows higher RPL31P17 RNA expression in tumor versus normal tissue (log2 FC = +0.393, t-test p < 0.001).
This table shows molecular features associated with RPL31P17 in patient tissues and cancer cell lines. In patient samples, RPL31P17 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
